about
Passive immunisation with monoclonal anti-Abeta antibodies for the treatment of Alzheimer's diseaseAutoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implicationsNew pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugsInteraction between therapeutic interventions for Alzheimer's disease and physiological Aβ clearance mechanismsTau-targeted treatment strategies in Alzheimer's diseaseAAV2/1 CD74 Gene Transfer Reduces β-amyloidosis and Improves Learning and Memory in a Mouse Model of Alzheimer's Disease.Immunotherapeutic approaches for Alzheimer's diseaseModulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanismsBapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapyGlial contributions to neurodegeneration in tauopathies.Oligomeric tau-targeted immunotherapy in Tg4510 mice.A new DNA vaccine fused with the C3d-p28 induces a Th2 immune response against amyloid-betaTau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice.Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide.Cell therapy: a safe and efficacious therapeutic treatment for Alzheimer's disease in APP+PS1 miceNovel immunological approaches for the treatment of Alzheimer's disease.Intravenous immunglobulin binds beta amyloid and modifies its aggregation, neurotoxicity and microglial phagocytosis in vitro.Is Apolipoprotein E4 an Important Risk Factor for Dementia in Persons with Down Syndrome?Co-immunization with DNA and protein mixture: a safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP miceThe mouse age phenome knowledgebase and disease-specific inter-species age mappingPeriodontal disease associates with higher brain amyloid load in normal elderly.Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's diseaseSingle chain variable fragment against aβ expressed in baculovirus inhibits abeta fibril elongation and promotes its disaggregation.Autoreactive-Aβ antibodies promote APP β-secretase processing.Could immunomodulation be used to prevent prion diseases?High-affinity Anticalins with aggregation-blocking activity directed against the Alzheimer β-amyloid peptide.Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer diseaseGlutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathologyMuscle-directed anti-Aβ single-chain antibody delivery via AAV1 reduces cerebral Aβ load in an Alzheimer's disease mouse model.Deep brain stimulation: a novel strategy for treating Alzheimer's disease.Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.Active immunotherapy for Alzheimer's disease.Cessation of neoangiogenesis in Alzheimer's disease follows amyloid-beta immunizationRole of neuroinflammation in adult neurogenesis and Alzheimer disease: therapeutic approachesGene therapy for misfolding protein diseases of the central nervous system.Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients.Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer's DiseaseIncreased Number of Plasma B Cells Producing Autoantibodies Against Aβ42 Protofibrils in Alzheimer's Disease.The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradationMycoplasma hyorhinis markedly degrades β-amyloid peptides in vitro and ex vivo: a novel biological approach for treating Alzheimer's disease?
P2860
Q24197852-1D201BA0-E526-4D28-A07A-7C9BDD398655Q26740418-0CF6444E-83FC-4E7C-99F6-993CBBBE4757Q26866006-52D0E8F8-E8D9-47EB-A603-4E4946825A07Q27001177-F625C696-5C86-4631-8D7F-61BCF8A05019Q27023429-0DAFD89A-EFD5-4233-8F81-F2616CCBB7B1Q27318148-8D2D3C7E-175F-491C-B286-CB07833F0FDAQ28081278-58F6F42A-A69E-4668-81C2-09E92A6CB0B4Q28259424-5BF9E729-5997-4503-B376-D2CA5A54C3A9Q28488690-36C47F07-7063-4B48-A4E4-53F60FF4A137Q32173558-9A59453C-2A0D-4A2C-945A-0C16215F8BAEQ33846761-5D7CA18A-13EF-4042-9364-C55E31B1FC4FQ34094661-D1CD55DF-99C0-4800-A091-23C4173E1A53Q34102829-601CCDDE-3496-4E3E-B850-35AD0497AF78Q34500145-EF843676-5203-4AA1-9DBB-3F4DE04E78FCQ34506405-FA1C4AA9-5637-4B3F-9640-23833F58EE07Q34562675-B7B3EEEA-E00B-4EC8-AF2E-F12F24AF36B1Q34733689-6243226E-B5CD-40E8-A9A5-B479EA4B9F4EQ34917679-7A20AAA6-B8AB-4DD6-AA81-44C67C57734FQ34948575-F8C48151-4FFA-4EAA-951E-E9E15C72E8E1Q35061186-025B2401-257A-45B8-81C4-C123D19DF698Q35447921-D4C195C8-5AAE-4A5E-9301-44B7933D5ECCQ35540628-890500D6-7E10-47E9-921C-517A0462D15EQ35616534-F13C37F4-B227-4E80-8959-457BCC7C7AA4Q35753932-81A0415E-D7C0-40BA-8BAC-CB547714431FQ35875915-15F35F71-DF30-45E8-B80B-CE31E16B03F6Q35974386-F1CE9F10-400F-4E7B-9C99-F9C1353762D7Q36478244-CE2CCD69-C43B-482C-A970-ECDA49CC75CAQ36485712-E8543815-55F8-47EB-9B6A-6A1858AED100Q36532822-752E06C6-64D3-4498-8083-816F26D77D58Q36555052-CE9520A3-D9BB-497A-B2ED-0C8EF69BC042Q36558485-640EB07C-7361-4EAF-BF00-967075F0BE4CQ36575898-A7AB8595-356F-497A-80FB-67755D754265Q36644869-7551954D-AA5F-4315-8B3B-63C355A4E75AQ36830938-53C1E5E2-80E3-43AD-AC11-B1E8CBC0EBEFQ36983203-2A337D60-1140-4E9E-AEDC-ADDFF6B24105Q37024947-F0FC117F-F835-4CF7-B82E-3EC6109FF316Q37044127-874757F9-060E-43B7-B0E8-4433B06A69A0Q37044228-2DA3DA6D-5137-48E4-AAE1-B5E157AEE588Q37085168-3725811A-FC68-41FE-97B3-CBC85BAA95EBQ37205567-94EE610F-F1C5-47EB-B1D6-E647E9207E33
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Immunotherapy for Alzheimer's disease.
@ast
Immunotherapy for Alzheimer's disease.
@en
Immunotherapy for Alzheimer's disease.
@nl
type
label
Immunotherapy for Alzheimer's disease.
@ast
Immunotherapy for Alzheimer's disease.
@en
Immunotherapy for Alzheimer's disease.
@nl
prefLabel
Immunotherapy for Alzheimer's disease.
@ast
Immunotherapy for Alzheimer's disease.
@en
Immunotherapy for Alzheimer's disease.
@nl
P2860
P1476
Immunotherapy for Alzheimer's disease.
@en
P2093
P2860
P356
10.1111/J.1365-2796.2010.02315.X
P407
P577
2011-01-01T00:00:00Z